Sony launches HD monitor

Sony has launched the LMD-2450MD monitor for use by medical professionals. The 24" monitor is the first HD 1080P model in Sony's healthcare range.

Fully compliant with CSA C 22.2 No. 60601 and EN60 601-1 safety regulations and UL60601-1 listed, the LMD-2450MD is suitable for use in a professional medical environment and its Full HD capability makes it well suited to critical endoscopic applications.

To enable accurate colour matching between different screens, Sony's ChromaTru technology eliminates inaccuracies that result from variations in LCD colour levels and adjusts white balance to deliver consistency throughout all grey-scale levels. The medical monitor also incorporates a super-wide aperture (1920 x 1200) WUXGA LCD panel to deliver clear, high-contrast images.

For optimum system performance, the LMD-2450MD offers a range of flexible set-up options. Multiple display modes - including ‘picture-in-picture' or ‘picture-and-picture' - provide comprehensive coverage of surgical procedures, and can be used to view both live video and captured images simultaneously.

To suit the medical context and the type of image being monitored, users can choose from 0% to 20% over-scan sizes, and aspect ratios can be set to either 16:9 or 4:3 to match the input signal. In addition, both CRT 2.2 and DICOM-standard gamma curve settings are available.

The LMD-2450MD can display images from a variety of medical equipment sources, including endoscopes. It accepts a wide range of SD, HD and PC signals, and provides parallel and serial control (including via Ethernet) as standard.

The monitor is fully compliant with the 100 mm VESA mounting standard and can be used with a surgical mount arm, making it well suited for use in operating theatres. Other convenient features include a key-inhibit function that prevents inadvertent changes to settings.

"The LMD-2450MD represents a leap forward in medical imaging technology," concludes Felip Garcia, European product marketing manager, Sony Europe. "It allows healthcare professionals to view still and moving pictures with high definition clarity and accurate image reproduction - helping them to carry out medical procedures with pinpoint precision."

TMC125 up for approval

Tibotec Pharmaceuticals has announced that the New Drug Application (NDA) for TMC125 (etravirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), has been accepted for priority review by the United States Food and Drug Administration (FDA). The Prescription Drug User Fee Act (PDUFA) user fee goal date for the NDA for TMC125, the date by which the FDA must announce its decision regarding the application, will be Friday, January 18, 2008. The NDA for TMC125, the first NNRTI to show antiviral activity in patients with documented NNRTI resistance, is based on the 24-week results of two ongoing Phase III randomised, double-blinded, placebo-controlled studies.

Print | Email | Discuss this article |

USER COMMENTS (0 COMMENTS)

POST A COMMENT

CLICK HERE TO POST A COMMENT

Add your Comment All posts are sent to the administrator for review and are published only after approval. ArabianBusiness.com reserves the right to remove any comment at any time for any reason. Please keep your responses appropriate and on topic.
Name *
Remember me on this computer
Email *	(Your email address will not be published)
City
Country
Subject *
Comment *
Notify me of further comments
Security Code *
Please click post only once - your comment will not be published immediately.